If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
07/06/2025 [06:53:00]
Results 125 to 138 of 138
Absstract of: US2024392374A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease. Disclosed is a method of differentiating between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having an inflammatory bowel disease (IBD) comprising determining a level of one or more of SEQ ID NOs: 1-590 in a sample from the subject.
Absstract of: US2024391994A1
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
Absstract of: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: US2024389885A1
Described herein are methods of utilizing single fasting methane breath concentrations to monitor, select treatment for, and to treat subjects having intestinal methanogen overgrowth.
Absstract of: US2024393333A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Absstract of: CN118995910A
The invention relates to application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis, and belongs to the technical field of molecular biomedicine. The invention provides Terrisporobacter spp, and application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis. According to the application, Terrisporobacter spp is selected as the marker for predicting the curative effect of treating UC by VDZ, UC patients can be distinguished to be sensitive to VDZ and not sensitive to VDZ, early diagnosis is conducted on VDZ sensitive patients, and the application has the advantages of being high in accuracy and sensitivity.
Absstract of: WO2024239006A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Absstract of: WO2024236584A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Absstract of: US2024384349A1
The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with with anti-α4β7 agent may be useful in a human suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent.
Absstract of: US2024383882A1
The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.
Absstract of: ES2988838A1
Method to predict the response of Crohn's disease patients to anti-TNF-α therapy based on plasma levels of vinculin together with the Crohn's disease activity index (CDAI), corticosteroid induction and bowel resection. (Machine-translation by Google Translate, not legally binding)
Absstract of: US2024376210A1
A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula (e) healing.
Nº publicación: CN118979093A 19/11/2024
Applicant:
QINGDAO NO ANTIBIOTICS BIOTECHNOLOGY CO LTD
\u9752\u5C9B\u8BFA\u5B89\u767E\u7279\u751F\u7269\u6280\u672F\u6709\u9650\u516C\u53F8
Absstract of: CN118979093A
The invention relates to the technical field of poultry pathogenic bacterium detection, in particular to a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by applying the detection culture medium. The invention discloses a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by using the detection culture medium. The content of clostridium perfringens in the excrement sample is judged according to the color change degree and the color change time, and then the infection degree of the chicken necrotic enteritis is obtained. Therefore, the method can be used for rapid detection on a breeding site, and has a wide application prospect.
BOPI
Electronic site
